Sarepta Therapeutics (NASDAQ:SRPT) saw its stock plummet in premarket trading Friday following the disclosure of a patient ...

Sarepta Therapeutics (NASDAQ:SRPT) saw its stock rise in after-hours trading following the announcement of a strategic review ...

The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

We believe that Sarepta Therapeutics stock ... SRPT and S&P 500 Performance Over 2007-08 Financial Crisis. SRPT stock plummeted from from levels of about $15 in October 2007 ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan ...

Despite A Q4 Miss Sarepta Therapeutics Stock Could See Higher Levels[Updated 3/2/2021] Sarepta Update Last month we talked about how Sarepta Therapeutics stock (NASDAQ: SRPT) seems to be a good ...

Sarepta Therapeutics (NASDAQ: SRPT) saw a lot of love from the market as the trading week kicked off on Monday. Investors pushed the stock almost 5% higher in price, a move due in no small part to ...

In a report released today, Kostas Biliouris from BMO Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $200.00. Discover outperforming ...

Sarepta hasn’t had a great year thus far with its stock plummeting over 52% from levels of around $165 toward the beginning of the year to $79 now.